

# Klaus Podar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5943627/publications.pdf>

Version: 2024-02-01

247  
papers

16,902  
citations

11235

73  
h-index

16186

128  
g-index

259  
all docs

259  
docs citations

259  
times ranked

16122  
citing authors

#	ARTICLE	IF	CITATIONS
1	On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future. Expert Opinion on Pharmacotherapy, 2022, 23, 1425-1444.	0.9	1
2	Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans. Clinical Cancer Research, 2021, 27, 1641-1649.	3.2	21
3	Pathway-Directed Therapy in Multiple Myeloma. Cancers, 2021, 13, 1668.	1.7	15
4	The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology. Cancers, 2021, 13, 2326.	1.7	24
5	JunB is a key regulator of multiple myeloma bone marrow angiogenesis. Leukemia, 2021, 35, 3509-3525.	3.3	19
6	Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). British Journal of Cancer, 2021, 125, 582-592.	2.9	4
7	Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients. Cancers, 2021, 13, 4312.	1.7	11
8	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer, 2021, 21, 993.	1.1	8
9	Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers, 2021, 13, 7.	1.7	13
10	Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. Cancers, 2021, 13, 5154.	1.7	30
11	Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity. Blood, 2021, 138, 2644-2644.	0.6	0
12	Delineating CDK9 Regulated Molecular Events for the Development of Rationally Derived Multiple Myeloma Treatment Strategies. Blood, 2021, 138, 1598-1598.	0.6	0
13	Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study). Blood, 2021, 138, 1669-1669.	0.6	0
14	Selinexor for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2020, 21, 399-408.	0.9	46
15	Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs, 2019, 24, 133-152.	1.0	20
16	Oral Selinexor+Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 381, 727-738.	13.9	460
17	Combined targeting of distinct c-Myc and JunB transcriptional programs for multiple myeloma therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e106-e107.	0.2	0
18	Targeting transcription factors in multiple myeloma: evolving therapeutic strategies. Expert Opinion on Investigational Drugs, 2019, 28, 445-462.	1.9	13

#	ARTICLE	IF	CITATIONS
19	Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. Breast Cancer Research and Treatment, 2019, 173, 585-596.	1.1	14
20	Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02). Blood, 2019, 134, 696-696.	0.6	4
21	Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis. Blood, 2019, 134, 4341-4341.	0.6	0
22	Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myeloma Therapy. Blood, 2019, 134, 4415-4415.	0.6	0
23	A role for bone turnover markers Î²-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma. Leukemia and Lymphoma, 2018, 59, 2431-2438.	0.6	10
24	The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. Annals of Hematology, 2018, 97, 839-849.	0.8	7
25	Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies. Pharmaceutics, 2018, 10, 202.	2.0	29
26	Choosing an appropriate salvage therapy for a patient with multiple myeloma. Expert Opinion on Pharmacotherapy, 2018, 19, 1511-1516.	0.9	1
27	Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. Expert Opinion on Pharmacotherapy, 2017, 18, 1061-1079.	0.9	5
28	Adoptive cell therapy in multiple Myeloma. Expert Opinion on Biological Therapy, 2017, 17, 1511-1522.	1.4	19
29	The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. Leukemia, 2017, 31, 1570-1581.	3.3	60
30	Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget, 2017, 8, 67639-67650.	0.8	26
31	Targeting the immune niche within the bone marrow microenvironment: The rise of immunotherapy in Multiple Myeloma. Current Cancer Drug Targets, 2017, 17, 1-1.	0.8	15
32	Editorial: Multiple Myeloma Immunotherapies. Current Cancer Drug Targets, 2017, 17, 768.	0.8	0
33	Targeting the Bone Marrow Microenvironment. Cancer Treatment and Research, 2016, 169, 63-102.	0.2	12
34	The Pathophysiologic Role of JunB in Multiple Myeloma Pathogenesis: Focus on Angiogenesis. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S77.	0.2	0
35	Prolyl Hydroxylase 3 Attenuates MCL-1â€“Mediated ATP Production to Suppress the Metastatic Potential of Colorectal Cancer Cells. Cancer Research, 2016, 76, 2219-2230.	0.4	16
36	Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Breast Cancer Research, 2016, 18, 26.	2.2	25

#	ARTICLE	IF	CITATIONS
37	Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway. PLoS ONE, 2016, 11, e0150507.	1.1	13
38	Abstract 2912: The AP-1 transcription factor JunB promotes multiple myeloma cell proliferation, survival and drug resistance in the bone marrow microenvironment. , 2016, , .		0
39	The Pathophysiologic Role of JunB in Multiple Myeloma Pathogenesis: Focus on Bone Marrow Angiogenesis. Blood, 2016, 128, 2091-2091.	0.6	0
40	Toward optimizing pomalidomide therapy in MM patients. Blood, 2015, 125, 3968-3969.	0.6	1
41	Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia, 2015, 29, 1555-1563.	3.3	48
42	Efficacy of Subcutaneous Bortezomib in the Management of Patients with Multiple Myeloma or Relapsed Mantle Cell Lymphoma. Clinical Medicine Insights Therapeutics, 2014, 6, CMT.S9308.	0.4	1
43	Targeting Mcl-1 for multiple myeloma (MM) therapy: Drug-induced generation of Mcl-1 fragment Mcl-1128â€“350 triggers MM cell death via c-Jun upregulation. Cancer Letters, 2014, 343, 286-294.	3.2	29
44	Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. Oncotarget, 2014, 5, 10237-10250.	0.8	22
45	Abstract 3383: JunB/AP-1 controls MM cell proliferation, survival and drug resistance in the bone marrow microenvironment. , 2014, , .		0
46	The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment. Blood, 2014, 124, 3446-3446.	0.6	2
47	New insights, recent advances, and current challenges in the biological treatment of multiple myeloma. Expert Opinion on Biological Therapy, 2013, 13, S35-S53.	1.4	9
48	Targeting Multiple Myeloma Tumor Angiogenesis: Focus on VEGF. , 2013, , 283-299.		1
49	Novel Targets and Derived Small Molecule Inhibitors in Multiple Myeloma. Current Cancer Drug Targets, 2012, 12, 797-813.	0.8	8
50	MM-associated anemia: more than â€œcrowding outâ€•HSPCs. Blood, 2012, 120, 2539-2540.	0.6	1
51	GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> . Cancer Research, 2012, 72, 5374-5385.	0.4	64
52	Ask the Experts: Deriving new treatment strategies in multiple myeloma. International Journal of Hematologic Oncology, 2012, 1, 21-26.	0.7	0
53	Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Expert Opinion on Pharmacotherapy, 2012, 13, 473-494.	0.9	16
54	Targeting the Tumor Microenvironment: Focus on Angiogenesis. Journal of Oncology, 2012, 2012, 1-16.	0.6	93

#	ARTICLE	IF	CITATIONS
55	Targeting Mcl-1 for Multiple Myeloma (MM) Therapy: Drug-Induced Generation of Mcl-1 Fragment Mcl-1128â€“350 Triggers MM Cell Death Via c- Jun Upregulation. <i>Blood</i> , 2012, 120, 3959-3959.	0.6	0
56	The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. <i>British Journal of Haematology</i> , 2011, 155, 438-448.	1.2	65
57	Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies. <i>Current Cancer Drug Targets</i> , 2011, 11, 1005-1024.	0.8	21
58	HIF regulation in tumor progression and angiogenesis and potential therapeutic agents. <i>Drugs of the Future</i> , 2011, 36, 391.	0.0	0
59	Abstract 660: Inhibition of centrosomal clustering suppresses tumor growth <i>in vivo</i> . , 2011, , .		0
60	Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic antiâ€“myeloma activity <i>in vitro</i> and <i>in vivo</i> . <i>British Journal of Haematology</i> , 2010, 149, 537-549.	1.2	119
61	Targeting the Ubiquitin-proteasome System for the Treatment of Multiple Myeloma and Other Human Diseases. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S2889.	0.4	0
62	A therapeutic role for targeting c-Myc/Hif-1- dependent signaling pathways. <i>Cell Cycle</i> , 2010, 9, 1722-1728.	1.3	72
63	Novel Oncogenic Mutations of CBL in Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism. <i>Journal of Biological Chemistry</i> , 2010, 285, 32596-32605.	1.6	42
64	The Evolution and Maintenance of the Multiple Myeloma Cell Clone within the Liquid Bone Marrow Compartment. , 2010, , 2799-2809.		0
65	The Pathophysiologic Role of the Bone Marrow Environment and its Niches in Multiple Myeloma. , 2010, , 2811-2819.		0
66	Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1. <i>Blood</i> , 2010, 116, 1838-1838.	0.6	0
67	Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1Î±â€“Dependent Pathway in Multiple Myeloma. <i>Cancer Research</i> , 2009, 69, 5082-5090.	0.4	89
68	Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells <i>in vitro</i> and <i>in vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2009, 8, 26-35.	1.9	57
69	Emerging therapies for multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 99-127.	1.0	48
70	Bortezomib induces canonical nuclear factor-Î² activation in multiple myeloma cells. <i>Blood</i> , 2009, 114, 1046-1052.	0.6	329
71	Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target. <i>Cancer Cell</i> , 2009, 16, 309-323.	7.7	242
72	Bone marrow microenvironment and the identification of new targets for myeloma therapy. <i>Leukemia</i> , 2009, 23, 10-24.	3.3	317

#	ARTICLE	IF	CITATIONS
73	Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. <i>Leukemia</i> , 2009, 23, 961-970.	3.3	65
74	Multiple myeloma. <i>Lancet</i> , The, 2009, 374, 324-339.	6.3	685
75	Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. <i>Blood</i> , 2009, 113, 1513-1521.	0.6	65
76	Biologic sequelae of I $\kappa$ B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. <i>Blood</i> , 2009, 113, 5228-5236.	0.6	70
77	BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. <i>Blood</i> , 2009, 114, 1813-1819.	0.6	51
78	CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. <i>Blood</i> , 2009, 113, 4309-4318.	0.6	75
79	Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2009, 114, 3276-3284.	0.6	38
80	Potential Therapeutic Role of the Selective Adhesion Molecule (SAM) Inhibitor Natalizumab in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 1850-1850.	0.6	1
81	Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.. <i>Blood</i> , 2009, 114, 3848-3848.	0.6	4
82	Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM).. <i>Blood</i> , 2009, 114, 295-295.	0.6	0
83	A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. <i>Oncogene</i> , 2008, 27, 721-731.	2.6	114
84	Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 6955-6962.	3.2	58
85	The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. <i>Blood</i> , 2008, 111, 3751-3759.	0.6	122
86	Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. <i>Blood</i> , 2008, 111, 1654-1664.	0.6	193
87	Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. <i>Blood</i> , 2008, 112, 1329-1337.	0.6	439
88	Novel Transforming Mutations of CBL in Human Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 2948-2948.	0.6	2
89	Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma. <i>Blood</i> , 2008, 112, 3662-3662.	0.6	3
90	The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 in Multiple Myeloma. <i>Blood</i> , 2008, 112, 2766-2766.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Mcl-1 Fragment Mcl-1(128-350) Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis Via Both Upregulation of C-Jun as Well as Modulation of Its Transcriptional Activity. <i>Blood</i> , 2008, 112, 2751-2751.	0.6	0
92	Canonical and Non Canonical Activation of Hedgehog Pathway in Multiple Myeloma. <i>Blood</i> , 2008, 112, 2748-2748.	0.6	0
93	Sp1 Transcription Factor as a Novel Therapeutic Target in Multiple Myeloma (MM). <i>Blood</i> , 2008, 112, 3664-3664.	0.6	0
94	Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs. <i>Blood</i> , 2008, 112, 2648-2648.	0.6	10
95	Targeting PKC: A Novel Role for Beta-catenin in ER Stress and Apoptotic Signaling. <i>Blood</i> , 2008, 112, 2763-2763.	0.6	0
96	C-Myc- Dependent Stabilization of Hif-1alpha in MM: Therapeutic Implications. <i>Blood</i> , 2008, 112, 2750-2750.	0.6	4
97	CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity Via C-Maf-Mediated Interactions with Bone Marrow Stromal Cells (BMSCs). <i>Blood</i> , 2008, 112, 840-840.	0.6	1
98	Inhibition of VEGF Signaling Pathways in Multiple Myeloma and Other Malignancies. <i>Cell Cycle</i> , 2007, 6, 538-542.	1.3	57
99	The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1693-1707.	1.9	48
100	Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma. <i>Cancer Research</i> , 2007, 67, 1680-1688.	0.4	56
101	Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. <i>Blood</i> , 2007, 110, 1656-1663.	0.6	106
102	Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). <i>Blood</i> , 2007, 109, 1220-1227.	0.6	144
103	Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). <i>Blood</i> , 2007, 109, 1669-1677.	0.6	126
104	Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenström macroglobulinemia. <i>Blood</i> , 2007, 109, 4964-4972.	0.6	100
105	MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. <i>Blood</i> , 2007, 110, 3744-3752.	0.6	144
106	Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 551-566.	1.1	12
107	The malignant clone and the bone-marrow environment. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 597-612.	0.7	78
108	A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. <i>Oncogene</i> , 2007, 26, 2374-2380.	2.6	207

#	ARTICLE	IF	CITATIONS
109	Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of $\beta$ -catenin/TCF pathway. <i>Leukemia</i> , 2007, 21, 535-540.	3.3	28
110	BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. <i>British Journal of Haematology</i> , 2007, 136, 414-423.	1.2	49
111	Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. <i>British Journal of Haematology</i> , 2007, 138, 783-791.	1.2	102
112	Inhibition of the TGF- $\beta$ Signaling Pathway in Tumor Cells. , 2007, 172, 77-97.		5
113	Niches Within the Multiple Myeloma Bone Marrow Microenvironment. <i>Translational Medicine Series</i> , 2007, , 61-74.	0.0	1
114	CS1, a New Surface Target on Multiple Myeloma (MM) Cells, Protects Myeloma Cells from Apoptosis Via Regulation of ERK1/2, AKT and STAT3 Signaling Cascades.. <i>Blood</i> , 2007, 110, 109-109.	0.6	2
115	Delineation of Canonical and Non-Canonical NF- $\kappa$ B Pathways in Multiple Myeloma: Therapeutic Implications.. <i>Blood</i> , 2007, 110, 670-670.	0.6	2
116	Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2524-2524.	0.6	1
117	Plasmacytoid Dendritic Cells Induce Growth and Survival of Multiple Myeloma Cells: Therapeutic Application.. <i>Blood</i> , 2007, 110, 3507-3507.	0.6	12
118	Activation of B-Cell Maturation Antigen (BCMA) on Human Multiple Myeloma Cells by a Proliferation-Inducing Ligand (APRIL) Promotes Myeloma Cell Function in the Bone Marrow Microenvironment.. <i>Blood</i> , 2007, 110, 1503-1503.	0.6	0
119	Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2503-2503.	0.6	0
120	Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.. <i>Blood</i> , 2007, 110, 256-256.	0.6	0
121	Inhibition of Hsp90 Targets Multiple Myeloma Cell Growth, Angiogenesis, and Osteoclastogenesis in the BM Microenvironment.. <i>Blood</i> , 2007, 110, 2522-2522.	0.6	0
122	BCR-ABL Induces Error-Prone Single Strand Annealing in Transformed Cells.. <i>Blood</i> , 2007, 110, 2937-2937.	0.6	0
123	The Tyrohostin Adaphostin (NSC680410) Inhibits Multiple Myeloma Bone Marrow Angiogenesis In Vitro and In Vivo.. <i>Blood</i> , 2007, 110, 2507-2507.	0.6	0
124	Targeting Proteinkinase C Alters ER-Stress and b-Catenin Signaling in Multiple Myeloma: Therapeutic Implications.. <i>Blood</i> , 2007, 110, 258-258.	0.6	0
125	Rational for a Combination of Bortezomib and Doxorubicin in the Treatment of Multiple Myeloma: A Pivotal Role for Mcl-1.. <i>Blood</i> , 2007, 110, 1501-1501.	0.6	0
126	Emerging Therapies for Multiple Myeloma. <i>American Journal of Cancer</i> , 2006, 5, 141-153.	0.4	2



#	ARTICLE	IF	CITATIONS
127	Role of B-Cell-Activating Factor in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment. <i>Cancer Research</i> , 2006, 66, 6675-6682.	0.4	212
128	The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 19478-19483.	3.3	189
129	Effects of PKC412, Nilotinib, and Imatinib Against GIST-Associated PDGFRA Mutants With Differential Imatinib Sensitivity. <i>Gastroenterology</i> , 2006, 131, 1734-1742.	0.6	93
130	Caveolin-1 as a potential new therapeutic target in multiple myeloma. <i>Cancer Letters</i> , 2006, 233, 10-15.	3.2	25
131	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. <i>Blood</i> , 2006, 107, 4053-4062.	0.6	398
132	FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. <i>British Journal of Haematology</i> , 2006, 132, 698-704.	1.2	4
133	Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib*. <i>British Journal of Haematology</i> , 2006, 134, 145-156.	1.2	94
134	MLN120B, a Novel I $\beta$ B Kinase I $\beta$ Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo. <i>Clinical Cancer Research</i> , 2006, 12, 5887-5894.	3.2	130
135	Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition. <i>Journal of Biological Chemistry</i> , 2006, 281, 18177-18183.	1.6	96
136	The Selective Protein Kinase CB Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2006, 108, 2496-2496.	0.6	2
137	Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.. <i>Blood</i> , 2006, 108, 3460-3460.	0.6	1
138	Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/ $\beta$ -Catenin Pathway.. <i>Blood</i> , 2006, 108, 5005-5005.	0.6	1
139	Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells.. <i>Blood</i> , 2006, 108, 3426-3426.	0.6	0
140	MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation.. <i>Blood</i> , 2006, 108, 1636-1636.	0.6	0
141	Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.. <i>Blood</i> , 2006, 108, 3410-3410.	0.6	0
142	The Jak2 V617F Oncogene Associated with Polycythemia Vera Requires a Functional FERM Domain for Transformation and for Expression of the Myc and Pim Proto-Oncogenes.. <i>Blood</i> , 2006, 108, 3611-3611.	0.6	2
143	The Small-Molecule VEGF-Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma.. <i>Blood</i> , 2006, 108, 5003-5003.	0.6	0
144	BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3440-3440.	0.6	0

#	ARTICLE	IF	CITATIONS
145	p38MAPK Inhibitor LSN2322600 Modulates the Bone Marrow Microenvironment and Inhibits Osteoclastogenesis in Multiple Myeloma.. Blood, 2006, 108, 5042-5042.	0.6	0
146	Targeting PKC in Multiple Myeloma: In Vitro and In Vivo Effects of the Novel, Orally Available Small-Molecule Inhibitor Enzastaurin (LY317615.HCl).. Blood, 2006, 108, 3466-3466.	0.6	0
147	The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication.. Blood, 2006, 108, 3452-3452.	0.6	1
148	Identification of Novel Antigens with Induced Immune Response in MGUS.. Blood, 2006, 108, 655-655.	0.6	0
149	In Vitro Generation of Highly Purified Functional Invariant NKT Cells in Multiple Myeloma: A Strategy for Immunotherapy.. Blood, 2006, 108, 5104-5104.	0.6	0
150	CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells.. Blood, 2006, 108, 3494-3494.	0.6	5
151	Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00.. Blood, 2006, 108, 3454-3454.	0.6	0
152	Upregulation of c-Jun Induces Cell Death Via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma.. Blood, 2006, 108, 3415-3415.	0.6	0
153	Bcl-2, Mcl-1 and p53 Expression Confer Sensitivity to Bcl-2 Inhibitor ABT-737 in Multiple Myeloma.. Blood, 2006, 108, 3474-3474.	0.6	0
154	Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood, 2005, 105, 350-357.	0.6	29
155	The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood, 2005, 105, 1383-1395.	0.6	310
156	Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood, 2005, 106, 1794-1800.	0.6	167
157	SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood, 2005, 106, 706-712.	0.6	54
158	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. British Journal of Haematology, 2005, 128, 192-203.	1.2	305
159	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)- $\beta$ inhibitors. Oncogene, 2005, 24, 3121-3129.	2.6	43
160	Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene, 2005, 24, 5888-5896.	2.6	56
161	A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell, 2005, 8, 407-419.	7.7	673
162	Human Anti-CD40 Antagonist Antibody Triggers Significant Antitumor Activity against Human Multiple Myeloma. Cancer Research, 2005, 65, 5898-5906.	0.4	146

#	ARTICLE	IF	CITATIONS
163	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications. <i>Cancer Research</i> , 2005, 65, 11712-11720.	0.4	163
164	FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance. <i>Cancer Research</i> , 2005, 65, 7478-7484.	0.4	97
165	Targeting signalling pathways for the treatment of multiple myeloma. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 359-381.	1.5	33
166	A Novel Carbohydrate-Based Therapeutic GCS-100 Overcomes Bortezomib Resistance and Enhances Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells. <i>Cancer Research</i> , 2005, 65, 8350-8358.	0.4	147
167	Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma. <i>Clinical Cancer Research</i> , 2005, 11, 4251-4258.	3.2	93
168	Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. <i>Blood</i> , 2005, 105, 1717-1723.	0.6	208
169	Cytokines and signal transduction. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 509-524.	0.7	78
170	The PKC- Inhibitor Enzastaurin Inhibits MM Cell Growth, Survival and Migration in the Bone Marrow Microenvironment.. <i>Blood</i> , 2005, 106, 1584-1584.	0.6	2
171	Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.. <i>Blood</i> , 2005, 106, 3378-3378.	0.6	1
172	Expression and Modulation of Carbohydrate-Binding Protein Galectin-3 in Multiple Myeloma Cells by Combined Treatment with GCS-100 and Dexamethasone.. <i>Blood</i> , 2005, 106, 4447-4447.	0.6	1
173	The JAK Inhibitor INCB20 Induces Antiproliferative and Apoptotic Effects in Human Myeloma Cells In Vitro and In Vivo.. <i>Blood</i> , 2005, 106, 3357-3357.	0.6	0
174	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.. <i>Blood</i> , 2005, 106, 5150-5150.	0.6	0
175	Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.. <i>Blood</i> , 2005, 106, 627-627.	0.6	0
176	R-Etodolac and a Novel Indole-Pyran Structural Analog, SDX-308, Induce Cytotoxicity and Overcome Drug Resistance in Multiple Myeloma.. <i>Blood</i> , 2005, 106, 1580-1580.	0.6	0
177	Targeting Src- Family Kinase Activation and Downstream Molecular Events To Overcome MM Cell Growth, Survival, and Drug- Resistance.. <i>Blood</i> , 2005, 106, 1583-1583.	0.6	1
178	In Vitro Generation of Highly-Purified Functional Invariant NKT Cells: A Strategy for Immunotherapy in Multiple Myeloma.. <i>Blood</i> , 2005, 106, 5183-5183.	0.6	0
179	Up-Regulation of c-Jun contributes to the Induction of Apoptosis by Adaphostin in Human Multiple Myeloma Cells.. <i>Blood</i> , 2005, 106, 1585-1585.	0.6	0
180	The Jak2V617F Oncogene Associated with Polycythemia Vera Regulates G1/S-Phase Transition.. <i>Blood</i> , 2005, 106, 3510-3510.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Perifosine, an Oral Bioactive Novel Alkyl-Phospholipid, Inhibits Akt and Induces In Vitro and In Vivo Cytotoxicity in Human Multiple Myeloma (MM) Cells.. Blood, 2005, 106, 250-250.	0.6	1
182	Mcl-1 Regulation and Its Role in Multiple Myeloma. Cell Cycle, 2004, 3, 1259-1262.	1.3	125
183	Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma. Cancer Research, 2004, 64, 8746-8753.	0.4	30
184	Critical Role for Hematopoietic Cell Kinase (Hck)-mediated Phosphorylation of Gab1 and Gab2 Docking Proteins in Interleukin 6-induced Proliferation and Survival of Multiple Myeloma Cells. Journal of Biological Chemistry, 2004, 279, 21658-21665.	1.6	60
185	Transforming Growth Factor $\beta$ 2 Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment. Clinical Cancer Research, 2004, 10, 7540-7546.	3.2	111
186	Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications. Cancer Research, 2004, 64, 2846-2852.	0.4	126
187	Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib. Cancer Research, 2004, 64, 7500-7506.	0.4	86
188	Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene, 2004, 23, 3597-3602.	2.6	54
189	p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene, 2004, 23, 8766-8776.	2.6	127
190	2-Methoxyestadiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. Apoptosis: an International Journal on Programmed Cell Death, 2004, 9, 149-155.	2.2	28
191	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti- $\mu$ multiple myeloma (MM) activity and overcome bortezomib resistance. Blood, 2004, 103, 3158-3166.	0.6	122
192	GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood, 2004, 103, 3474-3479.	0.6	87
193	Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood, 2004, 104, 2458-2466.	0.6	79
194	VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood, 2004, 104, 2886-2892.	0.6	147
195	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood, 2004, 104, 4188-4193.	0.6	177
196	A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.. Blood, 2004, 104, 2405-2405.	0.6	3
197	Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells.. Blood, 2004, 104, 2456-2456.	0.6	1
198	Vascular Endothelial Growth Factor (VEGF) Is a Growth and Survival Factor in Waldenstrom's Macroglobulinemia.. Blood, 2004, 104, 4892-4892.	0.6	2

#	ARTICLE	IF	CITATIONS
199	Pim Kinases Mediate Viability Signals Downstream of the Tyrosine Kinase Oncogenes BCR-ABL and FLT3-ITD.. Blood, 2004, 104, 557-557.	0.6	0
200	Effects of the Indazolympyrimidine GW786034 on Angiogenesis and MM Cell Growth: Therapeutic Implications.. Blood, 2004, 104, 2452-2452.	0.6	0
201	Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.. Blood, 2004, 104, 1498-1498.	0.6	2
202	Atiprimod (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. Blood, 2004, 104, 2401-2401.	0.6	0
203	JNK Activation and Fas Up-Regulation Precede Proteasomal Degradation of Topoisomerase I in SN38-Mediated Cytotoxicity Against Multiple Myeloma.. Blood, 2004, 104, 3413-3413.	0.6	3
204	VEGF Upregulates Mcl-1 Expression and Protects Multiple Myeloma Cells Against Starvation Induced-Apoptosis.. Blood, 2004, 104, 631-631.	0.6	0
205	Combination of the mTOR Inhibitor Rapamycin and Revlimidâ„¢ (CC-5013) Has Synergistic Activity in Multiple Myeloma (MM).. Blood, 2004, 104, 1492-1492.	0.6	1
206	TGF-Î² Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.. Blood, 2004, 104, 2355-2355.	0.6	1
207	Lack of Mcl-1 Confers Resistance to Bortezomid in Multiple Myeloma.. Blood, 2004, 104, 2445-2445.	0.6	0
208	Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib.. Blood, 2004, 104, 285-285.	0.6	1
209	Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-Î² Inhibitors.. Blood, 2004, 104, 2411-2411.	0.6	0
210	Anti-Tumor Activity of a Novel Immunosuppressant FTY720 in Multiple Myeloma.. Blood, 2004, 104, 3456-3456.	0.6	0
211	P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.. Blood, 2004, 104, 3348-3348.	0.6	0
212	Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor.. Blood, 2004, 104, 644-644.	0.6	0
213	Endothelial Cells Induce Multiple Myeloma Cell Proliferation Protect Against Conventional and Novel Therapies.. Blood, 2004, 104, 2354-2354.	0.6	1
214	Caveolin-1 Is Required for VEGF- Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (VelcadeÂ®).. Blood, 2004, 104, 2453-2453.	0.6	1
215	A Novel Inosine Monophosphate Dehydrogenase Inhibitor VX-944 Overcomes Conventional Drug-Resistance in Multiple Mueloma Cells in the Bone Marrow Microenvironment.. Blood, 2004, 104, 2468-2468.	0.6	1
216	Targeting Mitochondrial Factor Smac/DIABLO as Therapy for Multiple Myeloma (MM).. Blood, 2004, 104, 764-764.	0.6	0

#	ARTICLE	IF	CITATIONS
217	The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells.. Blood, 2004, 104, 3352-3352.	0.6	1
218	Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia, 2003, 17, 41-44.	3.3	173
219	Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene, 2003, 22, 6296-6300.	2.6	54
220	Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene, 2003, 22, 8386-8393.	2.6	163
221	JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells. Journal of Biological Chemistry, 2003, 278, 17593-17596.	1.6	180
222	Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells. Journal of Biological Chemistry, 2003, 278, 5794-5801.	1.6	128
223	Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 2003, 101, 1530-1534.	0.6	533
224	Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood, 2003, 101, 3606-3614.	0.6	67
225	Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood, 2003, 102, 3379-3386.	0.6	147
226	CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF- $\kappa$ B signaling. Blood, 2003, 101, 2762-2769.	0.6	111
227	A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Research, 2003, 63, 5462-9.	0.4	189
228	Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Research, 2003, 63, 5850-8.	0.4	159
229	Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Research, 2003, 63, 6174-7.	0.4	184
230	Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Research, 2003, 63, 8428-36.	0.4	54
231	Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with $\beta$ 1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKC $\delta$ Activation. Journal of Biological Chemistry, 2002, 277, 7875-7881.	1.6	161
232	Dephosphorylation of Ser-259 Regulates Raf-1 Membrane Association. Journal of Biological Chemistry, 2002, 277, 7913-7919.	1.6	108
233	CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood, 2002, 99, 1419-1427.	0.6	83
234	2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood, 2002, 100, 2187-2194.	0.6	110

#	ARTICLE	IF	CITATIONS
235	Critical role for Gab2 in transformation by BCR/ABL. <i>Cancer Cell</i> , 2002, 1, 479-492.	7.7	327
236	Translocation of Ku86/Ku70 to the multiple myeloma cell membrane. <i>Experimental Hematology</i> , 2002, 30, 212-220.	0.2	40
237	Î²-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. <i>Experimental Hematology</i> , 2002, 30, 711-720.	0.2	31
238	Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays. <i>Oncogene</i> , 2002, 21, 1346-1358.	2.6	170
239	The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. <i>Cancer Research</i> , 2002, 62, 5019-26.	0.4	128
240	The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 539-44.	1.9	101
241	Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. <i>Blood</i> , 2001, 98, 210-216.	0.6	869
242	Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. <i>Blood</i> , 2001, 98, 428-435.	0.6	399
243	Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. <i>Leukemia</i> , 2001, 15, 1950-1961.	3.3	536
244	Novel therapies targeting the myeloma cell and its bone marrow microenvironment. <i>Seminars in Oncology</i> , 2001, 28, 607-612.	0.8	164
245	Novel therapies targeting the myeloma cell and its bone marrow microenvironment. <i>Seminars in Oncology</i> , 2001, 28, 607-612.	0.8	130
246	Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage. <i>Journal of Immunology</i> , 2000, 165, 6347-6355.	0.4	45
247	Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation. <i>Journal of Biological Chemistry</i> , 2000, 275, 22300-22304.	1.6	200